Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy

BACKGROUND: Immune checkpoint inhibitor (ICI)-based combination therapy has opened a new avenue for the treatment of multiple malignancies including hepatocellular carcinoma (HCC). However, considering the unsatisfactory efficacy, biomarkers are urgently needed to identify the patients most likely t...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, De-Zhen, Zhang, Shi-Yu, Dong, San-Yuan, Yan, Jia-Yan, Wang, Yu-Peng, Cao, Ya, Rao, Sheng-Xiang, Fan, Jia, Yang, Xin-Rong, Huang, Ao, Zhou, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997675/
https://www.ncbi.nlm.nih.gov/pubmed/36910622
http://dx.doi.org/10.3389/fonc.2023.1109742

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997675/
https://www.ncbi.nlm.nih.gov/pubmed/36910622
http://dx.doi.org/10.3389/fonc.2023.1109742

Ejemplares similares